Two bespoke cell therapies developed by a small biotech firm called Iovance Biotherapeutics (IOVA) are inducing deep and durable tumor responses in patients with advanced melanoma and cervical cancer, according to updated results from clinical trials announced Friday.
The Iovance treatments, still experimental, are custom-built around immune cells called tumor infiltrating lymphocytes, or TILs. They are different from the more well-known and personalized T cell therapies called CAR-Ts that are approved to treat certain types of blood cancers.
About the Author Reprints
